The dual inhibitor PI3K/mTOR inhibitor PKI-587 (Gedatolisib) exhibited a significant inhibitory effect on T-ALL leukemia cells and in T-ALL patients with poor prognosis. Here, PIK3CD is linked to acute lymphoblastic leukemia.